Sernova Biotherapeutics Inc (SVA.TO)

Credit card sized pouch inserted under the skin into which insulin cells are inserted. Control highs and lows of insulin. Also works with thyroid cells. Distribution platform for many drugs. Very positive. Revolutionary. His 12-month price target is $2.50-3, subject to outcome of trials.

They produce a credit card-size device beneath the skin to produce to produce insulin and regulate body sugar levels. This helps diabetics and those with thyroid conditions. Testing results have been positive. He's optimistic about this.

Disclosure: He's helped with 2-3 of their financings recently. They make a credit-card sized pouch inserted under the skin that produces insulin to reduce extreme high or low insulin levels. That pouch can be used for many other applications in the future. Results are coming soon. SVA has broken out from 30 cents to 70 before the reports. There are strong opportunities for them in the coming year with potential deals with drugmakers and distributors.

They make a tiny device that you implant into your chest to create insulin. The medical benefits are high and could have additional applications. Tests are exploring how the device can deliver other drugs into the body, and early results are promising. He sees a lot of upside.

The company is researching insulin therapy delivery technology. They are moving into human trials. It has potential to go beyond insulin delivery systems to other drugs as well.

He participated in a recent financing. They have a piece that is inserted under the skin and then inject it with insulin. There are plans to use this for other needs as well.

They have an interesting implantable device that functions as an artificial pancreas. This replaces injecting insulin into diabetics. They are moving towards testing on people. It is quite positive.